000172519 001__ 172519
000172519 005__ 20240229133720.0
000172519 0247_ $$2doi$$a10.3390/nu13093132
000172519 0247_ $$2pmid$$apmid:34579010
000172519 0247_ $$2pmc$$apmc:PMC8470201
000172519 0247_ $$2altmetric$$aaltmetric:113183617
000172519 037__ $$aDKFZ-2021-02067
000172519 041__ $$aEnglish
000172519 082__ $$a610
000172519 1001_ $$aAglago, Elom K$$b0
000172519 245__ $$aDietary Advanced Glycation End-Products and Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study.
000172519 260__ $$aBasel$$bMDPI$$c2021
000172519 3367_ $$2DRIVER$$aarticle
000172519 3367_ $$2DataCite$$aOutput Types/Journal article
000172519 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1633686691_25366
000172519 3367_ $$2BibTeX$$aARTICLE
000172519 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000172519 3367_ $$00$$2EndNote$$aJournal Article
000172519 520__ $$aDietary advanced glycation end-products (dAGEs) have been hypothesized to be associated with a higher risk of colorectal cancer (CRC) by promoting inflammation, metabolic dysfunction, and oxidative stress in the colonic epithelium. However, evidence from prospective cohort studies is scarce and inconclusive. We evaluated CRC risk associated with the intake of dAGEs in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Dietary intakes of three major dAGEs: Nε-carboxy-methyllysine (CML), Nε-carboxyethyllysine (CEL), and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were estimated in 450,111 participants (median follow-up = 13 years, with 6162 CRC cases) by matching to a detailed published European food composition database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of dAGEs with CRC were computed using multivariable-adjusted Cox regression models. Inverse CRC risk associations were observed for CML (HR comparing extreme quintiles: HRQ5vs.Q1 = 0.92, 95% CI = 0.85-1.00) and MG-H1 (HRQ5vs.Q1 = 0.92, 95% CI = 0.85-1.00), but not for CEL (HRQ5vs.Q1 = 0.97, 95% CI = 0.89-1.05). The associations did not differ by sex or anatomical location of the tumor. Contrary to the initial hypothesis, our findings suggest an inverse association between dAGEs and CRC risk. More research is required to verify these findings and better differentiate the role of dAGEs from that of endogenously produced AGEs and their precursor compounds in CRC development.
000172519 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000172519 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000172519 650_7 $$2Other$$aadvanced glycation end-products
000172519 650_7 $$2Other$$acolorectal cancer
000172519 650_7 $$2Other$$adietary exposure
000172519 650_7 $$2Other$$adietary glycation compounds
000172519 7001_ $$aMayén, Ana-Lucia$$b1
000172519 7001_ $$aKnaze, Viktoria$$b2
000172519 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b3
000172519 7001_ $$aFedirko, Veronika$$b4
000172519 7001_ $$00000-0003-1668-8770$$aHughes, David J$$b5
000172519 7001_ $$00000-0002-0237-0262$$aJiao, Li$$b6
000172519 7001_ $$aEriksen, Anne Kirstine$$b7
000172519 7001_ $$00000-0003-4385-2097$$aTjønneland, Anne$$b8
000172519 7001_ $$aBoutron-Ruault, Marie-Christine$$b9
000172519 7001_ $$aRothwell, Joseph A$$b10
000172519 7001_ $$aSeveri, Gianluca$$b11
000172519 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b12$$udkfz
000172519 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b13$$udkfz
000172519 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b14
000172519 7001_ $$00000-0002-8306-3351$$aBirukov, Anna$$b15
000172519 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b16
000172519 7001_ $$00000-0001-5201-172X$$aSieri, Sabina$$b17
000172519 7001_ $$aSantucci de Magistris, Maria$$b18
000172519 7001_ $$aTumino, Rosario$$b19
000172519 7001_ $$aRicceri, Fulvio$$b20
000172519 7001_ $$aBueno-de-Mesquita, Bas$$b21
000172519 7001_ $$00000-0002-2973-5583$$aDerksen, Jeroen W G$$b22
000172519 7001_ $$00000-0003-2476-4251$$aSkeie, Guri$$b23
000172519 7001_ $$00000-0002-0031-4152$$aGram, Inger Torhild$$b24
000172519 7001_ $$aSandanger, Torkjel$$b25
000172519 7001_ $$aQuirós, J Ramón$$b26
000172519 7001_ $$00000-0001-6224-1764$$aLuján-Barroso, Leila$$b27
000172519 7001_ $$aSánchez, Maria-Jose$$b28
000172519 7001_ $$aAmiano, Pilar$$b29
000172519 7001_ $$aChirlaque, María-Dolores$$b30
000172519 7001_ $$aGurrea, Aurelio Barricarte$$b31
000172519 7001_ $$00000-0002-9227-8434$$aJohansson, Ingegerd$$b32
000172519 7001_ $$aManjer, Jonas$$b33
000172519 7001_ $$aPerez-Cornago, Aurora$$b34
000172519 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b35
000172519 7001_ $$aGunter, Marc J$$b36
000172519 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b37
000172519 7001_ $$aSchalkwijk, Casper G$$b38
000172519 7001_ $$aJenab, Mazda$$b39
000172519 773__ $$0PERI:(DE-600)2518386-2$$a10.3390/nu13093132$$gVol. 13, no. 9, p. 3132 -$$n9$$p3132 $$tNutrients$$v13$$x2072-6643$$y2021
000172519 909CO $$ooai:inrepo02.dkfz.de:172519$$pVDB
000172519 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000172519 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000172519 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000172519 9141_ $$y2021
000172519 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUTRIENTS : 2019$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000172519 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000172519 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000172519 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000172519 980__ $$ajournal
000172519 980__ $$aVDB
000172519 980__ $$aI:(DE-He78)C020-20160331
000172519 980__ $$aUNRESTRICTED